The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Onco‐miR‐155 targets SHIP1 to promote TNFα‐dependent growth of B cell lymphomas
Open accessAbstract
Non-coding microRNAs (miRs) are a vital component of post-transcriptional modulation of protein expression and, like coding mRNAs harbour oncogenic properties. However, the mechanisms governing miR expression and the identity of the affected transcripts remain poorly understood. Here we identify the inositol phosphatase SHIP1 as a bonafide target of the oncogenic miR-155. We demonstrate that in diffuse large B cell lymphoma (DLBCL) elevated levels of miR-155, and consequent diminished SHIP1 expression are the result of autocrine stimulation by the pro-inflammatory cytokine tumour necrosis factor a (TNFalpha). Anti-TNFalpha regimen such as eternacept or infliximab were sufficient to reduce miR-155 levels and restored SHIP1 expression in DLBCL cells with an accompanying reduction in cell proliferation. Furthermore, we observed a substantial decrease in tumour burden in DLBCL xenografts in response to eternacept. These findings strongly support the concept that cytokine-regulated miRs can function as a crucial link between inflammation and cancer, and illustrate the feasibility of anti-TNFalpha therapy as a novel and immediately accessible (co)treatment for DLBCL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., Rattan, S., Keating, M., Rai, K., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242606799 · Cited by 5,111
MicroRNA-155 is induced during the macrophage inflammatory response
O'Connell, R. M., Taganov, K. D., Boldin, M. P., Cheng, G., & Baltimore, D. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610731104 · Cited by 1,866
Tili, E., Michaille, J.-J., Cimino, A., Costinean, S., Dumitru, C. D., Adair, B., Fabbri, M., Alder, H., Liu, C. G., Calin, G. A., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.8.5082 · Cited by 1,304 · cited 1×
“…of GCs through the regulation of cytokine production (Thai et al, 2007). miR-155-deficiency was found to be associated with decreased TNF a production, a cytokine required for GC formation (Endres et al, 1999), whereas forced expression of miR-155 leads to elevated TNF a levels (Tili et al, 2007).”
Cited by
Molecular Mechanisms That Influence the Macrophage M1–M2 Polarization Balance
Wang, N., Liang, H., & Zen, K. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00614 · Cited by 1,980
Di Leva, G., Garofalo, M., & Croce, C. M. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104715 · Cited by 1,672
MicroRNAs in Development and Disease
Sayed, D., & Abdellatif, M. (2011) · Physiological Reviews · doi:10.1152/physrev.00006.2010 · Cited by 1,078
microRNA Regulation of Inflammatory Responses
O'Connell, R. M., Rao, D. S., & Baltimore, D. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075013 · Cited by 843
Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma
Babar, I. A., Cheng, C. J., Booth, C. J., Liang, X., Weidhaas, J. B., Saltzman, W. M., & Slack, F. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201516109 · Cited by 497
Kong, W., He, L., Richards, E. J., Challa, S., Xu, C.-X., Permuth-Wey, J., Lancaster, J. M., Coppola, D., Sellers, T. A., Djeu, J. Y., et al. (2014) · Oncogene · doi:10.1038/onc.2012.636 · Cited by 417
Kong, W., He, L., Coppola, M., Guo, J., Esposito, N. N., Coppola, D., & Cheng, J. Q. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.101055 · Cited by 377
RetractedBala, S., Marcos, M., Kodys, K., Csak, T., Catalano, D., Mandrekar, P., & Szabo, G. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.145870 · Cited by 361
Seto, A. G., Beatty, X., Lynch, J. M., Hermreck, M., Tetzlaff, M., Duvic, M., & Jackson, A. L. (2018) · British Journal of Haematology · doi:10.1111/bjh.15547 · Cited by 333
Sun, H.-X., Zeng, D.-Y., Li, R.-T., Pang, R.-P., Yang, H., Hu, Y.-L., Zhang, Q., Jiang, Y., Huang, L.-Y., Tang, Y.-B., et al. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.197301 · Cited by 319
The Oncogenic Role of miR-155 in Breast Cancer
Mattiske, S., Suetani, R. J., Neilsen, P. M., & Callen, D. F. (2012) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-12-0173 · Cited by 302
Lu, C., Huang, X., Zhang, X., Roensch, K., Cao, Q., Nakayama, K. I., Blazar, B. R., Zeng, Y., & Zhou, X. (2011) · Blood · doi:10.1182/blood-2010-12-322503 · Cited by 269
Macrophage polarization: the link between inflammation and related diseases
Bashir, S., Sharma, Y., Elahi, A., & Khan, F. (2016) · Inflammation Research · doi:10.1007/s00011-015-0874-1 · Cited by 267
Emerging avenues linking inflammation and cancer
Kundu, J. K., & Surh, Y.-J. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.02.035 · Cited by 264
MicroRNA replacement therapy in cancer
Mollaei, H., Safaralizadeh, R., & Rostami, Z. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28058 · Cited by 262
IL-10 Inhibits miR-155 Induction by Toll-like Receptors
McCoy, C. E., Sheedy, F. J., Qualls, J. E., Doyle, S. L., Quinn, S. R., Murray, P. J., & O'Neill, L. A. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.102111 · Cited by 256
miR-155 in cancer drug resistance and as target for miRNA-based therapeutics
Bayraktar, R., & Van Roosbroeck, K. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9724-7 · Cited by 216
Linnstaedt, S. D., Gottwein, E., Skalsky, R. L., Luftig, M. A., & Cullen, B. R. (2010) · Journal of Virology · doi:10.1128/jvi.01248-10 · Cited by 189
miR-155: An Important Role in Inflammation Response
Hu, J., Huang, S., Liu, X., Zhang, Y., Wei, S., & Hu, X. (2022) · Journal of Immunology Research · doi:10.1155/2022/7437281 · Cited by 171
The multiple roles of microRNA-155 in oncogenesis
Higgs, G., & Slack, F. (2013) · Journal of Clinical Bioinformatics · doi:10.1186/2043-9113-3-17 · Cited by 137
Zeng, Z., Gong, H., Li, Y., Jie, K., Ding, C., Shao, Q., Liu, F., Zhan, Y., Nie, C., Zhu, W., et al. (2013) · Experimental Lung Research · doi:10.3109/01902148.2013.808285 · Cited by 128
Role of microRNA-155 in autoimmunity
Leng, R.-X., Pan, H.-F., Qin, W.-Z., Chen, G.-M., & Ye, D.-Q. (2011) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2011.05.002 · Cited by 118
Pauls, S. D., & Marshall, A. J. (2017) · European Journal of Immunology · doi:10.1002/eji.201646795 · Cited by 118
Swaminathan, G., Rossi, F., Sierra, L.-J., Gupta, A., Navas-Martín, S., & Martín-García, J. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002937 · Cited by 103
New Perspectives in MicroRNA Regulation of Innate Immunity
Gantier, M. P. (2010) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2010.0037 · Cited by 82
The Effect of miR-132, miR-146a, and miR-155 on MRP8/TLR4-Induced Astrocyte-Related Inflammation
Kong, H., Yin, F., He, F., Omran, A., Li, L., Wu, T., Wang, Y., & Peng, J. (2015) · Journal of Molecular Neuroscience · doi:10.1007/s12031-015-0574-x · Cited by 81
Targeting SHIP1 and SHIP2 in Cancer
Pedicone, C., Meyer, S. T., Chisholm, J. D., & Kerr, W. G. (2021) · Cancers · doi:10.3390/cancers13040890 · Cited by 42
Brauer, H., Strauss, J., Wegner, W., Müller-Tidow, C., Horstmann, M., & Jücker, M. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.07.017 · Cited by 33
(2012) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Metadata
- Authors
- Pedersen, I. M., Otero, D., Kao, E., Miletic, A. V., Hother, C., Ralfkiaer, E., Rickert, R. C., Gronbaek, K., & David, M.
- Venue
- EMBO Molecular Medicine
- Published
- 2009-08
- Volume
- 1
- Issue
- 5
- Pages
- 288-295
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2118028558
- Cited by
- 209
- References
- 3
- FWCI
- 6.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.